CDK4 and breast cancer: Despite the study's limited sample size, PIK3CAm appear to correlate with poorer outcomes in advanced luminal BC patients treated with CDK4/6 inhibitors; significantly worse in exon 9 mutation carriers, regardless of visceral involvement and plasma detection, highlighting an urgent and unmet clinical concern.